Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milo Gatti

Showing results (111-120 of 168) with videos related to

Pageof 17
Sort By:
Paediatric Drugs|November 6, 2024
Therapeutic Drug Monitoring of Antimicrobial Drugs in Children with Cancer: A New Tool for Personalized MedicineRiccardo Masetti, Gianluca Bossù, Edoardo Muratore, et al.
Antibiotics (Basel, Switzerland)|October 27, 2022
Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre ExperienceMaria Mazzitelli, Milo Gatti, Vincenzo Scaglione, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|July 29, 2023
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients?Milo Gatti, Matteo Rinaldi, Luciano Potena, et al.
International Journal of Cancer|April 12, 2021
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysisDaria Maria Filippini, Milo Gatti, Vito Di Martino, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2025
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2025
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?Manjunath P Pai, Pier Giorgio Cojutti, Milo Gatti, et al.
International Journal of Antimicrobial Agents|March 6, 2023
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infectionsMilo Gatti, Pierluigi Viale, Pier Giorgio Cojutti, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2025
Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusionPier Giorgio Cojutti, Manjunath P Pai, Milo Gatti, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|October 22, 2022
The impact of preservation fluid culture on graft site arteritis: A systematic review and meta-analysisMatteo Rinaldi, Cecilia Bonazzetti, Milo Gatti, et al.
International Journal of Antimicrobial Agents|October 14, 2023
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study)Matteo Rinaldi, Michele Bartoletti, Cecilia Bonazzetti, et al.
Pageof 17

Showing results (111-120 of 168) with videos related to

Sort By:
Pageof 17
Paediatric Drugs|November 6, 2024
Therapeutic Drug Monitoring of Antimicrobial Drugs in Children with Cancer: A New Tool for Personalized MedicineRiccardo Masetti, Gianluca Bossù, Edoardo Muratore, et al.
Antibiotics (Basel, Switzerland)|October 27, 2022
Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre ExperienceMaria Mazzitelli, Milo Gatti, Vincenzo Scaglione, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|July 29, 2023
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients?Milo Gatti, Matteo Rinaldi, Luciano Potena, et al.
International Journal of Cancer|April 12, 2021
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysisDaria Maria Filippini, Milo Gatti, Vito Di Martino, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2025
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2025
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?Manjunath P Pai, Pier Giorgio Cojutti, Milo Gatti, et al.
International Journal of Antimicrobial Agents|March 6, 2023
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infectionsMilo Gatti, Pierluigi Viale, Pier Giorgio Cojutti, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2025
Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusionPier Giorgio Cojutti, Manjunath P Pai, Milo Gatti, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|October 22, 2022
The impact of preservation fluid culture on graft site arteritis: A systematic review and meta-analysisMatteo Rinaldi, Cecilia Bonazzetti, Milo Gatti, et al.
International Journal of Antimicrobial Agents|October 14, 2023
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study)Matteo Rinaldi, Michele Bartoletti, Cecilia Bonazzetti, et al.
Pageof 17